{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:36:25Z","timestamp":1792445785926,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the occurrence and frequency of anti-citrullinated protein antibodies (ACPA) to cyclic citrullinated type II collagen (COL2) epitope with a capacity to bind joint cartilage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Luminex immunoassay was used to analyze serum antibody reactivity to 10 COL2-citrullinated peptides (ACC10) and corresponding arginine peptide controls in rheumatoid arthritis (RA), osteoarthritis (OA), and healthy individuals\u2019 cohorts. Top ten \u201cpromiscuous\u201d sera (cross-reactive with all ACC10) and top ten \u201cprivate\u201d sera (restrictedly reactive with one ACC10 peptide) from RA and OA cohorts were selected. Enzyme-linked immunosorbent assay (ELISA) was used to detect response to native COL2. Sera were analyzed with naive and arthritic joints from DBA\/1J mice by immunohistochemistry, using monoclonal ACPAs and COL2 reactive antibodies with human Fc as comparison. Staining specificity was confirmed with C1 (a major antibody epitope on COL2) mutated mice and competitive blocking with epitope-specific antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patient sera bound ACC10 compared with control peptides but very few (3\/40) bound native triple-helical COL2. Most sera (27\/40) specifically bound to arthritic cartilage, whereas only one private RA serum bound to healthy cartilage. Despite very low titers, private sera from both RA and OA showed an epitope-specific response, documented by lack of binding to cartilage from C1-mutated mice and blocking binding to wild-type cartilage with a competitive monoclonal antibody. As a comparison, monoclonal ACPAs visualized typical promiscuous, or private reactivity to joint cartilage and other tissues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ACPA from RA and OA sera, reactive with citrullinated non-triple-helical COL2 peptides, can bind specifically to arthritic cartilage.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-022-02945-0","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T05:13:11Z","timestamp":1669180391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage"],"prefix":"10.1186","volume":"24","author":[{"given":"Qixing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingze","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"L\u00f6nnblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing\u2019an","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Stawikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changrong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg B.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianbo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikard","family":"Holmdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"6","key":"2945_CR1","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/eji.201444486","volume":"44","author":"R Holmdahl","year":"2014","unstructured":"Holmdahl R, Malmstr\u00f6m V, Burkhardt H. Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Eur J Immunol. 2014;44(6):1593\u20139.","journal-title":"Eur J Immunol"},{"key":"2945_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/art.1780280503","volume":"28","author":"K Aho","year":"1985","unstructured":"Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. When does rheumatoid disease start? Arthritis Rheum. 1985;28:485\u20139.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2945_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/art.1780350810","volume":"35","author":"P Kurki","year":"1992","unstructured":"Kurki P, Aho K, Palosuo T, Heli\u00f6vaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum. 1992;35(8):914\u20137.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2945_CR4","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantap\u00e4\u00e4-Dahlqvist","year":"2003","unstructured":"Rantap\u00e4\u00e4-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2945_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/art.20044","volume":"50","author":"FA van Gaalen","year":"2004","unstructured":"van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50(3):709\u201315.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2945_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI1316","volume":"101","author":"GA Schellekens","year":"1998","unstructured":"Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273\u201381.","journal-title":"J Clin Invest"},{"issue":"1","key":"2945_CR7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4049\/jimmunol.162.1.585","volume":"162","author":"E Girbal-Neuhauser","year":"1999","unstructured":"Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999;162(1):585\u201394.","journal-title":"J Immunol"},{"issue":"23","key":"2945_CR8","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205\u201319.","journal-title":"N Engl J Med"},{"issue":"3","key":"2945_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrrheum.2018.10","volume":"14","author":"HU Scherer","year":"2018","unstructured":"Scherer HU, Huizinga TWJ, Kr\u00f6nke G, Schett G, Toes REM. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(3):157\u201369.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"2945_CR10","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1002\/art.23936","volume":"58","author":"K Lundberg","year":"2008","unstructured":"Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum. 2008;58(10):3009\u201319.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2945_CR11","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.4049\/jimmunol.166.6.4177","volume":"166","author":"C Masson-Bessi\u00e8re","year":"2001","unstructured":"Masson-Bessi\u00e8re C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001;166(6):4177\u201384.","journal-title":"J Immunol"},{"issue":"5","key":"2945_CR12","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/eji.200526000","volume":"35","author":"H Burkhardt","year":"2005","unstructured":"Burkhardt H, Sehnert B, Bockermann R, Engstr\u00f6m A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol. 2005;35(5):1643\u201352.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2945_CR13","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar1149","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, Despr\u00e9s N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6(2):R142\u201350.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2945_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/art.40698","volume":"71","author":"C Ge","year":"2019","unstructured":"Ge C, Xu B, Liang B, L\u00f6nnblom E, Lundstr\u00f6m SL, Zubarev RA, et al. Structural basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis Rheum. 2019;71(2):210\u201321.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2945_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/anr.1780320906","volume":"32","author":"A Tarkowski","year":"1989","unstructured":"Tarkowski A, Klareskog L, Carlsten H, Herberts P, Koopman WJ. Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum. 1989;32(9):1087\u201392.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2945_CR16","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.38383","volume":"66","author":"S Haag","year":"2014","unstructured":"Haag S, Schneider N, Mason DE, Tuncel J, Andersson IE, Peters EC, et al. Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. Arthritis Rheum. 2014;66(6):1440\u20139.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2945_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41584-019-0244-4","volume":"15","author":"C Ge","year":"2019","unstructured":"Ge C, Holmdahl R. The structure, specificity and function of anti-citrullinated protein antibodies. Nat Rev Rheumatol. 2019;15(8):503\u20138.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"2945_CR18","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/rheumatology\/kez073","volume":"58","author":"B Liang","year":"2019","unstructured":"Liang B, Ge C, L\u00f6nnblom E, Lin X, Feng H, Xiao L, et al. The autoantibody response to cyclic citrullinated collagen type II peptides in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(9):1623\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2945_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/ard.49.10.753","volume":"49","author":"T Tuomi","year":"1990","unstructured":"Tuomi T, Heliovaara M, Palosuo T, Aho K. Smoking, lung function, and rheumatoid factors. Ann Rheum Dis. 1990;49(10):753\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"2945_CR20","first-page":"ii28","volume":"63","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, Alfredsson L, Rantapaa-Dahlqvist S, Berglin E, Stolt P, Padyukov L. What precedes development of rheumatoid arthritis? Ann Rheum Dis. 2004;63(Suppl 2):ii28\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2945_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","volume":"14","author":"VM Holers","year":"2018","unstructured":"Holers VM, Demoruelle MK, Kuhn KA, Buckner JH, Robinson WH, Okamoto Y, et al. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nat Rev Rheumatol. 2018;14(9):542\u201357.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2945_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1084\/jem.20081862","volume":"206","author":"H Uysal","year":"2009","unstructured":"Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstr\u00f6m A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med. 2009;206(2):449\u201362.","journal-title":"J Exp Med"},{"issue":"13","key":"2945_CR23","doi-asserted-by":"publisher","first-page":"e93688","DOI":"10.1172\/jci.insight.93688","volume":"2","author":"C Ge","year":"2017","unstructured":"Ge C, Tong D, Liang B, L\u00f6nnblom E, Schneider N, Hagert C, et al. Anti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage. JCI Insight. 2017;2(13):e93688.","journal-title":"JCI Insight"},{"issue":"4","key":"2945_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/ni772","volume":"3","author":"I Matsumoto","year":"2002","unstructured":"Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint- specific autoimmune disease. Nat Immunol. 2002;3(4):360\u20135.","journal-title":"Nat Immunol"},{"issue":"2","key":"2945_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/37.2.2911008","volume":"37","author":"R Jonsson","year":"1989","unstructured":"Jonsson R, Karlsson AL, Holmdahl R. Demonstration of immunoreactive sites on cartilage after in vivo administration of biotinylated anti-type II collagen antibodies. J Histochem Cytochem. 1989;37(2):265\u20138.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"2945_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13075-020-02169-0","volume":"22","author":"Y Li","year":"2020","unstructured":"Li Y, Tong D, Liang P, L\u00f6nnblom E, Viljanen J, Xu B, et al. Cartilage-binding antibodies initiate joint inflammation and promote chronic erosive arthritis. Arthritis Res Ther. 2020;22(1):120.","journal-title":"Arthritis Res Ther"},{"issue":"8453","key":"2945_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0140-6736(85)90436-2","volume":"2","author":"RS Pereira","year":"1985","unstructured":"Pereira RS, Black CM, Duance VC, Jones VE, Jacoby RK, Welsh KI. Disappearing collagen antibodies in rheumatoid arthritis. Lancet. 1985;2(8453):501\u20132.","journal-title":"Lancet"},{"issue":"4","key":"2945_CR28","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1186\/ar4605","volume":"16","author":"I Lindh","year":"2014","unstructured":"Lindh I, Snir O, L\u00f6nnblom E, Uysal H, Andersson I, Nandakumar KS, et al. Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates and mice. Arthritis Res Ther. 2014;16(4):R143.","journal-title":"Arthritis Res Ther"},{"key":"2945_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-981-13-3681-2_6","volume":"91","author":"PK Sacitharan","year":"2019","unstructured":"Sacitharan PK. Ageing and osteoarthritis. Subcell Biochem. 2019;91:123\u201359.","journal-title":"Subcell Biochem"},{"issue":"1","key":"2945_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3899\/jrheum.180256","volume":"46","author":"MAM van Delft","year":"2019","unstructured":"van Delft MAM, van Beest S. Presence of autoantibodies in erosive hand osteoarthritis and association with clinical presentation. J Rheumatol. 2019;46(1):101\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"2945_CR31","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.joca.2021.03.008","volume":"29","author":"X Xie","year":"2021","unstructured":"Xie X, van Delft MAM, Shuweihdi F, Kingsbury SR, Trouw LA, Doody GM, et al. Auto-antibodies to post-translationally modified proteins in osteoarthritis. Osteoarthritis Cartilage. 2021;29(6):924\u201333.","journal-title":"Osteoarthritis Cartilage"},{"issue":"9","key":"2945_CR32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/art.10472","volume":"46","author":"H Burkhardt","year":"2002","unstructured":"Burkhardt H, Koller T, Engstr\u00f6m A, Nandakumar KS, Turnay J, Kraetsch HG, et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum. 2002;46(9):2339\u201348.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2945_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"key":"2945_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/03009748709102175","volume":"65","author":"RD Altman","year":"1987","unstructured":"Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol Suppl. 1987;65:31\u20139.","journal-title":"Scand J Rheumatol Suppl"},{"issue":"11","key":"2945_CR35","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1021\/acschembio.0c00826","volume":"15","author":"J Viljanen","year":"2020","unstructured":"Viljanen J, L\u00f6nnblom E, Ge C, Yang J, Cheng L, Aldi S, et al. Correction to synthesis of an array of triple-helical peptides from type II collagen for multiplex analysis of autoantibodies in rheumatoid arthritis. ACS Chem Biol. 2020;15(11):3072.","journal-title":"ACS Chem Biol"},{"issue":"35","key":"2945_CR36","doi-asserted-by":"publisher","first-page":"E3669","DOI":"10.1073\/pnas.1405798111","volume":"111","author":"I Khmaladze","year":"2014","unstructured":"Khmaladze I, Kelkka T, Guerard S, Wing K, Pizzolla A, Saxena A, et al. Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. Proc Natl Acad Sci U S A. 2014;111(35):E3669\u201378.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2945_CR37","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.4049\/jimmunol.157.6.2440","volume":"157","author":"JA Mo","year":"1996","unstructured":"Mo JA, Holmdahl R. The B cell response to autologous type II collagen: biased V gene repertoire with V gene sharing and epitope shift. J Immunol. 1996;157(6):2440\u20138.","journal-title":"J Immunol"},{"issue":"2","key":"2945_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/annrheumdis-2017-211782","volume":"77","author":"J R\u00f6nnelid","year":"2018","unstructured":"R\u00f6nnelid J, Hansson M, Mathsson-Alm L, Cornillet M, Reed E, Jakobsson PJ, et al. Anticitrullinated protein\/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants. Ann Rheum Dis. 2018;77(2):203\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2945_CR39","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13075-020-02191-2","volume":"22","author":"E Reed","year":"2020","unstructured":"Reed E, Hedstr\u00f6m AK, Hansson M, Mathsson-Alm L, Brynedal B, Saevarsdottir S, et al. Presence of autoantibodies in \u201cseronegative\u201d rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther. 2020;22(1):170.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2945_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2015-208980","volume":"76","author":"AH Hensvold","year":"2017","unstructured":"Hensvold AH, Frisell T, Magnusson PK, Holmdahl R, Askling J, Catrina AI. How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins. Ann Rheum Dis. 2017;76(1):119\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2945_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nm0395-237","volume":"1","author":"R Malhotra","year":"1995","unstructured":"Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein [see comments]. Nat Med. 1995;1(3):237\u201343.","journal-title":"Nat Med"},{"issue":"4","key":"2945_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/oxfordjournals.jbchem.a022794","volume":"128","author":"A Matsumoto","year":"2000","unstructured":"Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem. 2000;128(4):621\u20138.","journal-title":"J Biochem"},{"key":"2945_CR43","doi-asserted-by":"crossref","unstructured":"Wouters F, Maurits MP, van Boheemen L, Verstappen M, Mankia K, Matthijssen XME, et al. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann Rheum Dis.\u00a02022;81(1):48\u201355.","DOI":"10.1136\/annrheumdis-2021-220546"},{"issue":"Suppl 2","key":"2945_CR44","first-page":"ii55","volume":"62 Suppl 2","author":"T Shaw","year":"2003","unstructured":"Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis. 2003;62 Suppl 2(Suppl 2):ii55\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2945_CR45","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1084\/jem.158.2.378","volume":"158","author":"JM Stuart","year":"1983","unstructured":"Stuart JM, Dixon FJ. Serum transfer of collagen induced arthritis in mice. J Exp Med. 1983;158:378\u201392.","journal-title":"J Exp Med"},{"key":"2945_CR46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/art.1780290314","volume":"29","author":"R Holmdahl","year":"1986","unstructured":"Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H. Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum. 1986;29:400\u201310.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2945_CR47","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1084\/jem.20181657","volume":"216","author":"A Bersellini Farinotti","year":"2019","unstructured":"Bersellini Farinotti A, Wigerblad G. Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons. J Exp Med. 2019;216(8):1904\u201324.","journal-title":"J Exp Med"},{"issue":"5","key":"2945_CR48","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0002-9440(10)63542-0","volume":"163","author":"KS Nandakumar","year":"2003","unstructured":"Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol. 2003;163(5):1827\u201337.","journal-title":"Am J Pathol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02945-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02945-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T16:29:53Z","timestamp":1678724993000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02945-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2945"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02945-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"28 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical data and patient samples were acquired from the Shanghai Guanghua Hospital and China Academy of Chinese Medical Sciences and patient samples were approved by the Ethics Committee of Guanghua Integrative Medicine Hospital, Shanghai, China (Ethical number: [2014]03). Written informed consent was obtained from the patients before inclusion. All animal experiments were conducted in accordance with the guidelines of the National Institutes of Health (NIH publication no. 8023) and approved by the Ethics Committee of Southern Medical University (L2020013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish all data in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RH is a founder of a small company (Vacara), which is currently developing a multiplex immune test. Other authors declare that they have no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}